Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials
Socinski, Mark A, Jotte, Robert M, Cappuzzo, Federico, Nishio, Makoto, Mok, Tony S K, Reck, Martin, Finley, Gene G, Kaul, Monika D, Yu, Wei, Paranthaman, Nindhana, Bara, Ilze, West, Howard J
Published in JAMA oncology (01.04.2023)
Published in JAMA oncology (01.04.2023)
Get more information
Journal Article
The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab
Smith, Katherine E R, Pritzl, Stephanie L, Yu, Wei, Bara, Ilze, Thanarajasingam, Gita, Kaul, Monika D, Williams, Kirstin A, Dueck, Amylou C, Mansfield, Aaron S
Published in JTO clinical and research reports (01.12.2023)
Published in JTO clinical and research reports (01.12.2023)
Get full text
Journal Article
Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer
Ardizzoni, Andrea, Azevedo, Sergio, Rubio-Viqueira, Belen, Rodriguez-Abreu, Delvys, Alatorre-Alexander, Jorge, Smit, Hans J M, Yu, Jinming, Syrigos, Konstantinos, Höglander, Elen, Kaul, Monika, Tolson, Jonathan, Hu, Youyou, Vollan, Hans Kristian, Newsom-Davis, Thomas
Published in Journal for immunotherapy of cancer (01.11.2022)
Published in Journal for immunotherapy of cancer (01.11.2022)
Get full text
Journal Article
Baseline autoantibody profiling in patients with NSCLC with pre-existing autoimmune diseases or who had received prior anti-PD-1 therapy before enrolling in the TAIL study
Rodriguez-Abreu, Delvys, Budde, Petra Ilse, Zucht, Hans-Dieter, Shrivastava, Divya, Kilian, Annika Loredana, Höglander, Elen, Shoshkova, Stefaniya, Markovic, Marija, Kaul, Monika Dulloo, Cardona, Jose Vicente, Chandler, G Scott, Mohindra, Rajat
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study
Reck, Martin, Dziadziuszko, Rafal, Sugawara, Shunichi, Kao, Steven, Hochmair, Maximilian, Huemer, Florian, de Castro, Gilberto, Havel, Libor, Bernabé Caro, Reyes, Losonczy, György, Lee, Jong-Seok, Kowalski, Dariusz M., Andric, Zoran, Califano, Raffaele, Veatch, Andrea, Gerstner, Gregory, Batus, Marta, Morris, Stefanie, Kaul, Monika, Cuchelkar, Vaikunth, Li, Huafei, Danner, Bradford J., Nabet, Barzin Y., Liu, Stephen V.
Published in Lung cancer (Amsterdam, Netherlands) (01.10.2024)
Published in Lung cancer (Amsterdam, Netherlands) (01.10.2024)
Get full text
Journal Article
Abstract CT009: IMvoke010: A phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)
Wong, Deborah J., Fayette, Jérôme, Teixeira, Maria, Prabhash, Kumar, Mesia, Ricard, Kawecki, Andrzej, Dechaphunkul, Arunee, Dinis, José, Guo, Ye, Masuda, Muneyuki, Hsieh, Ching-Yun, Ghi, Maria Grazia, de Melo Sette, Claudia Vaz, Jiang, Tao, Yan, Yibing, Kaul, Monika, Jagtiani, Ritika, Matheny, Christina, Cuchelkar, Vaikunth, Haddad, Robert
Published in Cancer research (Chicago, Ill.) (05.04.2024)
Published in Cancer research (Chicago, Ill.) (05.04.2024)
Get full text
Journal Article